Jun 2026 (Q2 FY26) — Aug 13, 2026
Ascendis Pharma Q2 FY26 — Strong TransCon Product Uptake and Pipeline Advancement
Read the full callAscendis Pharma (ASND) earnings
- Jun 2026 (Q2 FY26)
- Dec 2025
Ascendis Pharma earnings: last reported Thu, 13 Aug 2026, for the quarter ended Jun 2026.
Guidance
What management said, and what became of it
17 of 17 judged targets kept · 17 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| COACH trial enrollment completion | Complete enrollment in COACH trial | Jun 2024 | Our recent week 78 cost tried data show sustained efficacy over 78 weeks. | Achieved |
| Cash flow from operating activities | > EUR 500 million | Jun 2026 | Even with these investments, we expect to generate more than EUR 500 million in cash flow from operating activities this year. | New |
17 of Ascendis Pharma A/S's 34 targets are still open. See which are on track and which have gone quiet. The 2 above are the free sample; 32 more targets are in the full ledger.
Claimed
- Total product revenue more than doubled year-over-year to EUR 315 million.
- YORVIPATH revenue reached EUR 252 million in Q2, achieving blockbuster status on a run rate basis in its second year.
- YUVIWEL generated EUR 8 million in revenue in its first quarter on the market, with over 220 patients enrolled and >65% approved for reimbursement by end of July.
- SKYTROFA achieved over 20,000 unique enrollments, maintaining its position as the #1 long-acting growth hormone by brand value in the U.S.
- Non-IFRS operating profit was EUR 92 million, with a non-IFRS operating margin of 27%.
Qualified
- Ongoing ITC legal battle with BioMarin regarding YUVIWEL patent, with a first opinion expected in August and a full ITC decision in December.
- R&D expenses increased to EUR 76 million in Q2 from EUR 59 million in Q1, reflecting continued pipeline investment.
- SG&A expenses increased to EUR 173 million in Q2 from EUR 145 million in Q1, driven by commercial launch investments.
Price
$226.62 −0.17% · −$0.38
Performance +8.6% 1Y
1Y: $208.71 on 14 Oct 2025 → $226.62. High $277.18 (8 Jul 2026), low $196.01 (10 Nov 2025).
- Previous close
- $227
- 52-week range
- $196.01 – $277.18
- One year
- +9.41%
Overview
- Symbol
- ASND
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Exchange
- US
- Currency
- USD
Guidance
What management said, and what became of it
17 of 17 judged targets kept · 17 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| COACH trial enrollment completion | Complete enrollment in COACH trial | Jun 2024 | Our recent week 78 cost tried data show sustained efficacy over 78 weeks. | Achieved |
| Cash flow from operating activities | > EUR 500 million | Jun 2026 | Even with these investments, we expect to generate more than EUR 500 million in cash flow from operating activities this year. | New |
Claimed
- Total product revenue more than doubled year-over-year to EUR 315 million.
- YORVIPATH revenue reached EUR 252 million in Q2, achieving blockbuster status on a run rate basis in its second year.
- YUVIWEL generated EUR 8 million in revenue in its first quarter on the market, with over 220 patients enrolled and >65% approved for reimbursement by end of July.
- SKYTROFA achieved over 20,000 unique enrollments, maintaining its position as the #1 long-acting growth hormone by brand value in the U.S.
- Non-IFRS operating profit was EUR 92 million, with a non-IFRS operating margin of 27%.
Qualified
- Ongoing ITC legal battle with BioMarin regarding YUVIWEL patent, with a first opinion expected in August and a full ITC decision in December.
- R&D expenses increased to EUR 76 million in Q2 from EUR 59 million in Q1, reflecting continued pipeline investment.
- SG&A expenses increased to EUR 173 million in Q2 from EUR 145 million in Q1, driven by commercial launch investments.
The full ledger
Open Ascendis Pharma A/S’s full ledger
A free account opens 5 company ledgers a month. All 34 tracked commitments, with each call’s wording and source.
Call summaries
Mar 2026 (Q1 FY26) — May 7, 2026
Ascendis Pharma Q1 FY26 — Strong Revenue Growth and YUVIWEL Launch
Read the full callEvery analysed call
Ascendis Pharma earnings calls (ASND)
Financials
What the filings say
| Line item | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total liabilities | 29 | 45 | 89 | 173 | 228 | 1,073 | 1,335 | 1,722 |
| Fixed assets | 3 | 5 | 51 | 133 | 143 | 122 | 103 | 172 |
| Total assets | 253 | 365 | 760 | 1,202 | 1,229 | 912 | 1,225 | 1,531 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -159 | -198 | -333 | -473 | -529 | -516 | -318 | 63 |
| Cash from investing | -3 | -6 | -357 | -125 | 66 | 317 | 7 | -10 |
| Cash from financing | 233 | 555 | 740 | 398 | 423 | 148 | 461 | 43 |
| Capital expenditure | -3 | -6 | -24 | -27 | -15 | -3 | — | — |
| Free cash flow | -162 | -203 | -358 | -500 | -544 | -519 | — | — |
Insider filings
13 filings between May 11, 2026 and Sep 8, 2026.
Open market
decisions to buy or sellPurchases
$777.1K
9 purchases by 2 insiders
Sales
$5.51M
3 sales by 3 insiders
Compensation
not trading decisions- 1
- Option exercise — converted options into shares
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| JENSEN FLEMMING STEEN | — | $4.64M | May 11, 2026 |
| Bodenhoff Mads | — | $810.6K | Sep 8, 2026 |
| BIENAIME JEAN JACQUES | $699.3K | — | Aug 14, 2026 |
| SMITH SCOTT THOMAS | $77.7K | — | Jun 2, 2026 |
| HOLTUG LARS | — | $62.3K | Sep 2, 2026 |
Latest filings (13)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 8, 2026 | Bodenhoff Mads SVP & PAO | Option exercise | 3,000 | $330.0K |
| Sep 8, 2026 | Bodenhoff Mads SVP & PAO | Sale | 3,000 | $810.6K |
| Sep 2, 2026 | HOLTUG LARS Director | Sale | 236 | $62.3K |
| Aug 14, 2026 | BIENAIME JEAN JACQUES Director | Purchase | 1,100 | $270.4K |
| Aug 14, 2026 | BIENAIME JEAN JACQUES Director | Purchase | 900 | $222.2K |
| Jun 2, 2026 | SMITH SCOTT THOMAS EVP & Chief Financial Officer | Purchase | 100 | $21.9K |
| May 29, 2026 | BIENAIME JEAN JACQUES Director | Purchase | 100 | $22.4K |
| May 29, 2026 | BIENAIME JEAN JACQUES Director | Purchase | 200 | $44.5K |
| May 29, 2026 | BIENAIME JEAN JACQUES Director | Purchase | 200 | $44.8K |
| May 29, 2026 | SMITH SCOTT THOMAS EVP & Chief Financial Officer | Purchase | 250 | $55.8K |
| May 26, 2026 | BIENAIME JEAN JACQUES Director | Purchase | 200 | $47.2K |
| May 26, 2026 | BIENAIME JEAN JACQUES Director | Purchase | 200 | $47.9K |
| May 11, 2026 | JENSEN FLEMMING STEEN See Remarks | Sale | 19,460 | $4.64M |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Ascendis Pharma A/S
Free account. Everything above stays public.
Write why you follow Ascendis Pharma A/S and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading